1. Introduction {#sec1-molecules-20-17208}
===============

The value of 1,3-oxazolidine derivatives, which are found in many natural products and synthetic complex compounds, lies in their utility in drugs, agrochemicals, dyes, and organic synthesis of a wide range of biologically-important compounds \[[@B1-molecules-20-17208],[@B2-molecules-20-17208],[@B3-molecules-20-17208],[@B4-molecules-20-17208],[@B5-molecules-20-17208],[@B6-molecules-20-17208],[@B7-molecules-20-17208],[@B8-molecules-20-17208],[@B9-molecules-20-17208],[@B10-molecules-20-17208]\]. Thus, highly efficient and creative synthetic methods of 1,3-oxazolidine skeleton is an attractive topic in organic synthesis \[[@B11-molecules-20-17208],[@B12-molecules-20-17208],[@B13-molecules-20-17208]\]. As a result, more and more efficient syntheses of 1,3-oxazolidine derivatives were reported utilizing intramolecular cyclization and intermolecular cycloaddition \[[@B14-molecules-20-17208],[@B15-molecules-20-17208]\]. Cascade reaction, an ecologically- and economically-favorable method, was considered to fall under the banner of "green chemistry" because of its atom and resource economy \[[@B16-molecules-20-17208],[@B17-molecules-20-17208],[@B18-molecules-20-17208],[@B19-molecules-20-17208]\], as well as time efficiency \[[@B20-molecules-20-17208],[@B21-molecules-20-17208],[@B22-molecules-20-17208],[@B23-molecules-20-17208],[@B24-molecules-20-17208],[@B25-molecules-20-17208],[@B26-molecules-20-17208],[@B27-molecules-20-17208],[@B28-molecules-20-17208],[@B29-molecules-20-17208]\]. However, cascade reaction has not been used to construct 1,3-oxazolidine skeleton up to date. Application of more efficient multicomponent cascade reactions to replace traditional single-step-procedure reactions in constructing 1,3-oxazolidine skeleton is still an interesting topic.

On the other hand, kinetic resolution, a powerful strategy in asymmetric synthesis, makes racemic substrates into optically-pure compounds \[[@B30-molecules-20-17208],[@B31-molecules-20-17208],[@B32-molecules-20-17208],[@B33-molecules-20-17208],[@B34-molecules-20-17208],[@B35-molecules-20-17208],[@B36-molecules-20-17208],[@B37-molecules-20-17208],[@B38-molecules-20-17208],[@B39-molecules-20-17208],[@B40-molecules-20-17208],[@B41-molecules-20-17208]\]. Although many methods towards 1,3-oxazolidine skeletons have been developed, asymmetric synthesis of 1,3-oxazolidine with three components reaction involving kinetic resolution has not been well studied \[[@B42-molecules-20-17208],[@B43-molecules-20-17208],[@B44-molecules-20-17208],[@B45-molecules-20-17208],[@B46-molecules-20-17208],[@B47-molecules-20-17208],[@B48-molecules-20-17208],[@B49-molecules-20-17208],[@B50-molecules-20-17208],[@B51-molecules-20-17208],[@B52-molecules-20-17208],[@B53-molecules-20-17208]\].

The reaction of imine with aldehyde is a well-established one, for example, Ishii group described a method to synthesize 1,3-oxazolidines from a multi-step synthesis of imines and epoxides \[[@B13-molecules-20-17208]\]. However, the reaction yields were relatively low and the stereochemistry was not explained. Herein, we describe an efficient multi-component reaction to access 1,3-oxazolidine compounds of high optical purity. The plausible mechanism of the reaction was suggested and a kinetic resolution of the epoxides process was confirmed. All of products were well-characterized and the absolute configuration of the chiral center from the epoxides part was determined. To the best of our knowledge \[[@B54-molecules-20-17208],[@B55-molecules-20-17208]\], this is the first report of synthesis of 1,3-oxazolidine with a multi-component reaction via the kinetic resolution from epoxides, anilines, and ethyl glyoxalate.

2. Results and Discussion {#sec2-molecules-20-17208}
=========================

The formal references about 1,3-oxazolidine all required multi-step reactions \[[@B56-molecules-20-17208],[@B57-molecules-20-17208],[@B58-molecules-20-17208],[@B59-molecules-20-17208],[@B60-molecules-20-17208],[@B61-molecules-20-17208]\]. When we investigated the reactions of anilines, ethyl glyoxalate, and epoxides by one-pot asymmetric multi-component reaction, products with 1,3-oxazolidine structure were obtained ([Scheme 1](#molecules-20-17208-f004){ref-type="scheme"}).

![Asymmetric multi-component reaction of anilines, ethyl glyoxalate, and epoxides.](molecules-20-17208-g004){#molecules-20-17208-f004}

The reaction conditions optimization of three-component reactions was carried out, a variety of different chiral Lewis acid (**4a**--**4d**) catalysts were screened ([Figure 1](#molecules-20-17208-f001){ref-type="fig"}).

![Chiral ligands used in this work.](molecules-20-17208-g001){#molecules-20-17208-f001}

First we examined the reaction of aniline **1a**, ethylglyoxalate, and epoxide **2a** in dichloromethane at 18 °C in the presence of catalyst **4a** (10 mol %), while the reaction gave the product in only 5% yield with poor diastereoselectivity and enantioselectivity after two days ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entry 1). Little higher yield and *ee* value were achieved when catalyst **4b** was applied ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entry 2). With this encouragement, the product with a higher *ee* was obtained when the reaction was carried out at −10 °C ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entry 3). Catalyst **4c**/Ti(IV), which was prepared by mixing **4c** and Ti(O-*i*-Pr)~4~ in 1:1 molar ratio in dichloromethane for 2 h, afforded a moderate *ee* of 41% ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entry 4). On the contrary, when the reaction was carried out with catalyst **4c**/Ti(IV), which was prepared in a 1:1 molar ratio in toluene, good diastereoselectivity and enantioselectivity trifluoroacetic acid (TFA) (0.5 mol %) was added, the product with a good yield was obtained ([Table 1](#molecules-20-17208-t001){ref-type="table"} were provided ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entry 5). To our delight, after a small amount of, entry 6). Therefore, it is indicated that TFA was very important for the cyclization. TFA might be beneficial for the ring-opening of epoxide. However, when TFA was used as the only catalyst, the reaction rate was not accelerated, and completion of the reaction also needed a long time at room temperature. Catalyst **4c**/Ti(IV) was prepared in a 2:1 molar ratio in toluene, affording better *ee* value ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entry 7). Slightly lower yield was observed for the reaction carried out with the catalyst **4d**/Ti(IV), which was prepared in a 2:1 molar ratio in toluene ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entry 8). The influence of temperature to the reaction was also investigated ([Table 1](#molecules-20-17208-t001){ref-type="table"}, entries 9 and 10), the decrease of temperature were negative to the yields. It could be concluded that the molar ratio of **4c** and Ti(IV) influenced the enantioselectivity and TFA strongly benefited the yields.

Theoretically, the products had C-5 isomer and C-4 isomer, but the C-4 isomer was only separated and actually detected when different reaction scales from 1 mmol to 10 mmol were conducted ([Figure 2](#molecules-20-17208-f002){ref-type="fig"}). The C-5 isomer was not found. Furthermore, NMR spectra, such as ^1^H-^1^H NOESY, and HMBC could prove that the structure of the desired product belongs to the C-4 isomer. The H~11~ had the chemical shift value of 4.56 ppm because it was adjacent to an oxygen atom. It had heteronuclear coupling with C~10~ and C~12~. Accordingly, C~6~ had heteronuclear coupling with H~10~ and H~11~ (see [Supporting Information](#app1-molecules-20-17208){ref-type="app"}).

![Isomer characterization of the product.](molecules-20-17208-g002){#molecules-20-17208-f002}

molecules-20-17208-t001_Table 1

###### 

Catalyst screening and optimization of the three-component reactions ^a^.

![](molecules-20-17208-i001.jpg)

  Entry    Solvent      Catal.          T (°C)   Yield (%) ^b^   d.r. ^c^   *ee* (%) ^d^
  -------- ------------ --------------- -------- --------------- ---------- --------------
  1        CH~2~Cl~2~   **4a**          18       5               2:1        10
  2        CH~2~Cl~2~   **4b**          18       13              3:1        15
  3        CH~2~Cl~2~   **4b**          −10      13              2:1        30
  4 ^e^    CH~2~Cl~2~   **4c**/Ti(IV)   −40      13              3:1        41
  5 ^e^    PhCH~3~      **4c**/Ti(IV)   −40      15              4:1        60
  6 ^e^    PhCH~3~      **4c**/Ti(IV)   −40      50              4:1        61
  7 ^f^    PhCH~3~      **4c**/Ti(IV)   −40      53              11:1       72
  8 ^f^    PhCH~3~      **4d**/Ti(IV)   −40      36              11:1       72
  9 ^f^    PhCH~3~      **4c**/Ti(IV)   −55      30              12:1       73
  10 ^f^   PhCH~3~      **4c**/Ti(IV)   −70      15              12:1       73

^a^ **1a** (1.1 mmol) and ethyl glyoxalate (1.0 mmol) were stirred for 1 h in 1.5 mL solvent, then **2a** (0.2 mmol) and catalyst (0.1 mmol) were added, and the system was stirred for 4 days; ^b^ Yields of isolated products; ^c,d^ were determined by HPLC on a chiral column; ^e^ Catalysts were prepared by Ti(IV) and **4c** ligand in a 1:1 molar ratio and TFA was added into the reactions as a catalyst; ^f^ Catalysts were prepared by Ti(IV) and **4c**, **4d** ligands in a 1:2 molar ratio and TFA was added into the reactions as a catalyst.

The three-component reactions of anilines, ethyl glyoxalate, and epoxides were expanded under the optimized conditions ([Table 2](#molecules-20-17208-t002){ref-type="table"}). A series of chiral 1,3-oxazolidine derivatives in moderate yields with good diastereoselectivities and enantioselectivities was provided, such as 4-chloroaniline, affording good *ee* and diastereoselectivity ([Table 2](#molecules-20-17208-t002){ref-type="table"}, entries 2, 8, and 9). Product **3h** was obtained with a good enantioselectivity ([Table 2](#molecules-20-17208-t002){ref-type="table"}, entry 8). Product **3i** was obtained with the highest *ee* (up to 90%) ([Table 2](#molecules-20-17208-t002){ref-type="table"}, entry 9). From entries 1, 2, 3, and 11 in [Table 2](#molecules-20-17208-t002){ref-type="table"}, we found that the *ee* changed with group R^1^. The electron-withdrawing group was negative for the reaction, such as entry 11 in [Table 2](#molecules-20-17208-t002){ref-type="table"}. Therefore, substrates bearing electron-donating substituents were advantageous to the reaction. We speculated the reaction is a kinetic resolution as the yields are around 50%. Thus, the reaction of entry 10 ([Table 2](#molecules-20-17208-t002){ref-type="table"}) also had been carried out as controlled experiment. Racemic (±)-epoxystyrene was used as substrate to react with ethyl glyoxalate and anisidine under the condition listed in [Table 2](#molecules-20-17208-t002){ref-type="table"}. When the reaction was finished, unreacted epoxystyrene was subjected into a chiral column on the HPLC. To our delight, the epoxystyrene recollected from the reaction is no longer racemic, according to the HPLC analysis. Instead of the substrate racemic (±)-epoxystyrene, unreacted epoxystyrene with 68% *ee* was obtained. This means one enantiomer of the racemic epoxystyrene was consumed and the other was kept and the reaction is indeed a kinetic resolution (see [Supporting Information](#app1-molecules-20-17208){ref-type="app"}).

To understand more about the reaction, effort also has been made to determine the absolute configuration of the products. Firstly, we figured out the retention time of (*R*)-epoxystyrene and (*S*)-epoxystyrene by detecting the racemic (±)-epoxystyrene and a standard (*R*)-epoxystyrene. Then, we reclaimed unreacted epoxystyrene from the reaction of entry 10 in [Table 2](#molecules-20-17208-t002){ref-type="table"}, by checking the retention time. We found (*S*)-epoxystyrene was consumed and (*R*)-epoxystyrene not. This means that the absolute configuration of the chiral center from epoxides in the product is *S*-configuration \[[@B10-molecules-20-17208]\]. (see [Supporting Information](#app1-molecules-20-17208){ref-type="app"}).

On the basis of previous studies and the results of our experiments \[[@B13-molecules-20-17208],[@B42-molecules-20-17208],[@B43-molecules-20-17208],[@B44-molecules-20-17208],[@B45-molecules-20-17208],[@B46-molecules-20-17208],[@B47-molecules-20-17208],[@B48-molecules-20-17208],[@B49-molecules-20-17208],[@B50-molecules-20-17208],[@B51-molecules-20-17208],[@B52-molecules-20-17208],[@B53-molecules-20-17208]\], a possible reaction mechanism of the present reaction is proposed. Firstly, (*S*)-BINOL reacted with Ti(O-*i*-Pr)~4~ for two hours to give a complex **A**. When racemic epoxide **B** was added, a transition state **C** was formed by the complexation of **A** and (*S*)-epoxide with the influence of TFA. Immediately, **C** reacted with the imine from aniline and ethyl glyoxalate to give the target product **D**, releasing out complexes **A** to participate the next cycle at the same time ([Figure 3](#molecules-20-17208-f003){ref-type="fig"}).

molecules-20-17208-t002_Table 2

###### 

Three-component reaction of anilines, ethyl glyoxalate, and epoxides ^a^.

![](molecules-20-17208-i002.jpg)

  Entry   3        R^1^          R^2^                    Yield (%) ^b^   d.r. ^c^   *ee* (%) ^d^
  ------- -------- ------------- ----------------------- --------------- ---------- --------------
  1       **3a**   CH~3~O        CH~2~Cl                 52              12:1       43
  2       **3b**   Cl            CH~2~Cl                 50              10:1       69
  3       **3c**   CH~3~CH~2~O   CH~2~Cl                 47              10:1       39
  4       **3d**   CH~3~O        CH~2~OCH(CH~3~)~2~      56              4:1        43
  5       **3e**   CH~3~O        CH~2~O(CH~2~)~3~CH~3~   46              1.5:1      71
  6       **3f**   CH~3~CH~2~O   CH~2~O(CH~2~)~3~CH~3~   53              3:1        34
  7       **3g**   CH~3~CH~2~O   CH~2~OCH(CH~3~)~2~      53              3:1        72
  8       **3h**   Cl            CH~2~O(CH~2~)~3~CH~3~   48              3:1        69
  9       **3i**   Cl            CH~2~OCH(CH~3~)~2~      54              4:1        90
  10      **3j**   CH~3~O        Ph                      42              1.7:1      84.6
  11      **3k**   NO~2~         CH~2~Cl                 trace           ―          ―

^a^ Reactions were carried out under optimum conditions; ^b^ Yields of isolated products; ^c^determined by ^1^H-NMR; ^d^ determined by HPLC on a chiral column.

![Proposed reaction mechanism.](molecules-20-17208-g003){#molecules-20-17208-f003}

3. Experimental Section {#sec3-molecules-20-17208}
=======================

3.1. General Procedure for the Synthesis of All 1,3-Oxazolidines {#sec3dot1-molecules-20-17208}
----------------------------------------------------------------

Ti(O-*i*-Pr)~4~ (0.05 mmol) and chiral binaphthalene ligand (**4c**, 0.10 mmol) were dissolved in 2.0 mL toluene, and the mixture was stirred for 2 h at room temperature, then aniline (1.1 mmol) and ethyl glyoxalate (1.0 mmol) were added into the mixture, and the result system was stirred for 30 min. Finally epoxide (1.2 mmol) and TFA (0.5 mol %) were added into the system and were stirred at −40 °C for four days. Then, the solvent was evaporated under vacuum. The residue was purified by silica gel column chromatography using 1:5 ethyl acetate/petroleum ether as eluent, giving a light yellow liquid. Enantiomeric excess (*ee*) were determined by HPLC analysis on a L-7420 (UV-VIS Detector with an L-7110 pump and a Chiralcel OD-H column). We determined the retention time of the product is based on significant changes in HPLC on a chiral column.

3.2. Characterization Data for All of the Compounds {#sec3dot2-molecules-20-17208}
---------------------------------------------------

*Ethyl 5-(chloromethyl)-3-(4-methoxyphenyl)oxazolidine-2-carboxylate* (**3a~1~**) Light yellow liquid; R*~f~* = 0.46 (1:5 ethyl acetate:petroleum ether); 48% yield (pure **3a~1~**). The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 0.5 mL/min, λ = 254 nm), t~R~ = 8.92 min (major), t~R~ = 10.397 min (minor), 43% *ee*; ^1^H-NMR (400 MHz, CDCl~3~) δ 6.82 (d, *J* = 6.8 Hz, 2H), 6.69 (d, *J* = 6.8 Hz, 2H), 5.42 (s, 1H), 4.58--4.55 (m, 1H), 4.18--4.16 (m, 2H), 3.84--3.80 (m, 1H), 3.78--3.72 (m, 5H), 3.56--3.52 (m, 1H), 1.23 (t, *J* = 7.2 Hz, 3H). ^13^C-NMR (100 MHz, CDCl~3~) δ 170.2, 153.9, 138.7, 116.0, 115.0, 89.7, 78.6, 61.6, 55.8, 51.5, 44.834, 14.2. HRMS (EI^+^) exact mass calculated for C~14~H~18~ClNO~4~ \[M\]^+^ requires *m*/*z* 299.0924, found *m*/*z* 299.0937.

*Ethyl 5-(chloromethyl)-3-(4-methoxyphenyl)oxazolidine-2-carboxylate* (**3a~2~**) Light yellow liquid; R*~f~* = 0.36 (1:5 ethyl acetate:petroleum ether); 4% yield (pure **3a~2~**). ^1^H-NMR (400 MHz, CDCl~3~) δ 6.84 (d, *J* = 6.8 Hz, 2H), 6.67 (d, *J* = 6.8 Hz, 2H), 5.46 (s, 1H), 4.92--4.88 (m, 1H), 4.22--4.16 (m, 2H), 3.78--3.69 (m, 5H), 3.65--3.60 (m, 1H), 3.43--3.39 (m, 1H), 1.25 (t, *J* = 7.2 Hz, 3H). ^13^C-NMR (100 MHz, CDCl~3~) δ 169.3, 152.6, 138.3, 114.5, 114.0, 88.3, 77.6, 60.9, 55.2, 49.6, 44.3, 13.7. HRMS (EI^+^) exact mass calculated for C~14~H~18~ClNO~4~ \[M\]^+^ requires *m*/*z* 299.0924, found *m*/*z* 299.0937.

*Ethyl 5-(chloromethyl)-3-(4-chlorophenyl)oxazolidine-2-carboxylate* (**3b~1~**) Light yellow liquid; R*~f~* = 0.57 (1:5 ethyl acetate:petroleum ether); 46% yield (pure **3b~1~**). The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 1 mL/min, λ = 254 nm), t~R~ = 12.13 min (major), t~R~ = 8.09 min (minor), 61.1% *ee* (minor); ^1^H-NMR (400 MHz, CDCl~3~) δ 7.19 (d, *J* = 6.8 Hz, 2H), 6.59 (d, *J* = 6.8 Hz, 2H), 5.45 (s, 1H), 4.63--4.59 (m, 1H), 4.19--4.17 (m, 2H), 3.83--3.79 (m, 2H), 3.76--3.71 (m, 1H), 3.56--3.52 (m, 1H), 1.24 (t, *J* = 7.2 Hz, 3H). ^13^C-NMR (100 MHz, CDCl~3~) δ 169.8, 142.695, 129.4, 124.5, 115.0, 88.5, 78.8, 61.9, 50.5, 44.7, 14.2. HRMS (EI^+^) exact mass calculated for C~13~H~15~Cl~2~NO~3~ \[M\]^+^ requires *m*/*z* 303.0429, found *m*/*z* 303.0424.

*Ethyl 5-(chloromethyl)-3-(4-chlorophenyl)oxazolidine-2-carboxylate* (**3b~2~**) Light yellow liquid; R*~f~* = 0.46 (1:5 ethyl acetate:petroleum ether); 4% yield (pure **3b~2~**). ^1^H-NMR (400 MHz, CDCl~3~) δ 7.21 (d, *J* = 6.8 Hz, 2H), 6.62 (d, *J* = 6.8 Hz, 2H), 5.48 (s, 1H), 4.97--4.94 (m, 1H), 4.23--4.21 (m, 2H), 3.79--3.72 (m, 2H), 3.68--3.64 (m, 1H), 3.45--3.42 (m, 1H), 1.28 (t, *J* = 7.2 Hz, 3H). ^13^C-NMR (100 MHz, CDCl~3~) δ 170.8, 144.2, 130.7, 125.3, 115.6, 89.4, 79.3, 63.1, 50.9, 45.8, 15.5. HRMS (EI^+^) exact mass calculated for C~13~H~15~Cl~2~NO~3~ \[M\]^+^ requires *m*/*z* 303.0429, found *m*/*z* 303.0424.

*Ethyl 5-(chloromethyl)-3-(4-ethoxyphenyl)oxazolidine-2-carboxylate* (**3c~1~**) Light yellow liquid; R*~f~* = 0.48 (1:5 ethyl acetate:petroleum ether); 47% yield (**3c~1~**). The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 0.5 mL/min, λ = 254 nm), t~R~ = 7.79 min (major), t~R~ = 8.57 min (minor), 39% *ee*; ^1^H-NMR (400 MHz, CDCl~3~) δ 6.83 (d, *J* = 6.8 Hz, 2H), 6.65 (d, *J* = 6.8 Hz, 2H), 5.45 (s, 1H), 4.93--4.87 (m, 1H), 4.20--4.16 (m, 2H), 4.00--3.94 (m, 2H), 3.79--3.69 (m, 2H), 3.64--3.61 (m, 1H), 3.43--3.39 (m, 1H), 1.38 (t, *J* = 7.2 Hz, 3H), 1.24 (t, *J* = 7.2 Hz, 3H). ^13^C-NMR (100 MHz, CDCl~3~) δ 169.9, 152.5, 138.8, 115.9, 114.6, 88.9, 78.1, 64.2, 61.5, 50.2, 44.7, 15.1, 14.3. HRMS (EI^+^) exact mass calculated for C~15~H~20~ClNO~4~ \[M + H\]^+^ requires *m*/*z* 314.1154, found *m*/*z* 314.1155.

*Ethyl 5-(isopropoxymethyl)-3-(4-methoxyphenyl)oxazolidine-2-carbo-xylate* (**3d**) (**diastereoisomers**): Light yellow liquid; R*~f~* = 0.33 (1:5 ethyl acetate:petroleum ether); 56% yield. The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 0.5 mL/min, λ = 254 nm), t~R~ = 18.40 min (major), t~R~ = 19.12 min (minor), 41.5% *ee* (minor); ^1^H-NMR (400 MHz, CDCl~3~) δ 6.85--6.81 (m, 2H\[\[2Hʹ\]), 6.66--6.63 (m, 2H\[\[2Hʹ\]), 5.39 (s, 1H) and 5.42, (s, 1Hʹ)\], 4.84--4.80 (m, 1H\[\[1Hʹ\]), 4.21--4.13 (m, 2H\[\[2Hʹ\]), 3.75 (s, 3H), 3.68--3.60 (m, 2H), 3.59--3.55 (m, 2H), 3.43--3.25 (m, 1H\[\[1Hʹ\]), 1.25 (t, *J* = 7.2 Hz, 3H), 1.21--1.15 (m, 6H). ^13^C-NMR (100 MHz, CDCl~3~) δ 170.2 153.0, 139.3 115.0 and \[\[115.4, (1Cʹ)\], 114.3 88.7 and \[\[88.8, (1Cʹ)\], 78.0, 72.5, 69. and \[\[69.8 (1Cʹ)\], 61.3, 55.8, 49.6 and \[\[49.8, (1Cʹ)\], 22.1, 14.2 HRMS (EI^+^) exact mass calculated for C~17~H~25~NO~5~ \[M\]^+^ requires *m*/*z* 323.1733, found *m*/*z* 323.1743.

*Ethyl 5-(butoxymethyl)-3-(4-methoxyphenyl)oxazolidine-2-carboxylate* (**3e**) (**diastereoisomers**): Light yellow liquid; R*~f~* = 0.44 (1:5 ethyl acetate:petroleum ether); 46% yield. The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 0.5 mL/min, λ = 254 nm), t~R~ = 19.49 min (major), t~R~ = 22.00 min (minor), 71% *ee*; ^1^H-NMR (400 MHz, CDCl~3~) δ 6.876.83 (m, 2H\[\[2Hʹ\]), 6.68--6.66 (m, 2H\[\[2Hʹ\]), 5.41 (s, 1H) and 5.44 (s, 1Hʹ), 4.874.50 (m, 1H\[\[1Hʹ\]), 4.224.15 (m, 2H\[\[2Hʹ\]), 3.77 (s, 3H), 3.68--3.62 (m, 2H\[\[2Hʹ\]), 3.543.50 m, 2H\[\[2Hʹ\]), 3.43--3.27 (m, 2H\[\[2Hʹ\]), 1.68--1.57 (m, 4H), 1.42--1.35 (m, 3H), 1.29--1.21 (m, 3H\[\[3Hʹ\]). ^13^C-NMR (100 MHz, CDCl~3~) δ 169.7, 152.3, 138.9, 114.4 and \[\[115.0, (1Cʹ)\], 113.8, 88.1 (1C) and \[\[88.6, (1Cʹ)\], 77.2, 70.9, 60.7, 55.2, 50.4 and \[\[49.8, (1Cʹ)\], 48.9, 43.780, 31.3, 18.7, 13.4. HRMS (EI^+^) exact mass calculated for C~18~H~27~NO~5~ \[M\]^+^ requires *m*/*z* 337.1889, found *m*/*z* 337.1886.

*Ethyl 5-(butoxymethyl)-3-(4-ethoxyphenyl)oxazolidine-2-carboxylate* (**3f**) (**diastereoisomers**): Light yellow liquid; R*~f~* = 0.43 (1:5 ethyl acetate:petroleum ether); 53% yield. The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 1 mL/min, λ = 254 nm), t~R~ = 7.94 min (major), t~R~ = 8.47 min (minor), 34.5% *ee* (minor); ^1^H-NMR (400 MHz, CDCl~3~) δ 6.84--6.80 (m, 2H\[\[2Hʹ\]), 6.64--6.61 (m, 2H\[\[2Hʹ\]), 5.38 (s, 1H) and \[\[5.41, (s, 1Hʹ)\], 4.84--4.45 (m, 1H\[\[1Hʹ\]), 4.21--4.16 (m, 2H\[\[2Hʹ\]), 3.99--3.93 (m, 2H), 3.68--3.60 (m, 2H\[\[2Hʹ\]), 3.51--3.47 (m, 2H), 3.40--3.25 (m, 2H\[\[2Hʹ\]), 1.59--1.54 (m, 4H), 1.40--1.33 (m, 6H), 1.27--1.1837 (m, 3H\[\[3Hʹ\]). ^13^C-NMR (100 MHz, CDCl~3~) δ 170.37, 152.2, 139.4, 115.8, 114.2, 88.7 and \[\[88.7, (1Cʹ)\], 77.8, 71.5, 64.13, 61.3, 51.0 and \[\[50.4, (1Cʹ)\], 49.4, 44.4, 31.7, 19.3, 15.0, 14.0. HRMS (ESI^+^) exact mass calculated for \[M + Na\]^+^ requires *m*/*z* 374.1944, found *m*/*z* 374.1935.

*Ethyl 3-(4-ethoxyphenyl)-5-(isopropoxymethyl)oxazolidine-2-carboxylate* (**3g**) (**diastereoisomers**): Light yellow liquid; R*~f~* = 0.43 (1:5 ethyl acetate:petroleum ether); 53% yield. The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 1 mL/min, λ = 254 nm), t~R~ = 6.59 min (major), t~R~ = 7.90 min (minor), 72% *dr*; ^1^H-NMR (400 MHz, CDCl~3~) δ 6.85--6.81 (m, 2H\[\[2Hʹ\]), 6.66--6.62 (m, 2H\[\[2Hʹ\]), 5.40 (s, 1H) and \[\[5.42, (s, 1Hʹ)\], 4.82--4.81 (m, 1H\[\[1Hʹ\]), 4.22--4.14 (m, 2H\[\[2Hʹ\]), 4.00--3.94 (m, 2H\[\[2Hʹ\]), 3.69--3.65 (m, 2H\[\[2Hʹ\]), 3.64--3.55 (m, 2H\[\[2Hʹ\]), 3.29--3.26 (m, 1H\[\[1Hʹ\]), 1.38 (t, *J* = 7.2 Hz, 3H), 1.27--1.23 (m, 3H), 1.20--1.16 (m, 6H). ^13^C-NMR (100 MHz, CDCl~3~) δ 169.8, 151.6, 138.9, 115.3, 113.7, 88.1 and \[\[88.2, (1Cʹ)\], 77.4, 71.9, 68.4 and \[\[69.2, (1Cʹ)\], 63.6, 60.7, 49.0 and \[\[50.0, (1Cʹ)\], 21.5, 14.5, 13.6. HRMS (EI^+^) exact mass calculated for C~18~H~27~NO~5~ \[M\]^+^ requires *m*/*z* 337.1889, found *m*/*z* 337.1881.

*Ethyl 5-(butoxymethyl)-3-(4-chlorophenyl)oxazolidine-2-carboxylate* (**3h**) (**diastereoisomers**): Light yellow liquid; R*~f~* = 0.57 (1:5 ethyl acetate:petroleum ether); 48% yield. The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 1 mL/min, λ = 254 nm), t~R~ = 4.74 min (major), t~R~ = 6.18 min (minor), 69*.*4% *ee* (major); ^1^H-NMR (400 MHz, CDCl~3~) δ 7.20--7.17 (m, 2H\[\[2Hʹ\]), 6.59--6.54 (m, 2H\[\[2Hʹ\]), 5.40 (s, 1H) and \[\[5.44, (s, 1Hʹ)\], 4.87--4.53 (m, 1H\[\[1Hʹ\]), 4.23--4.15 (m, 2H\[\[2Hʹ\]), 3.67--3.61 (m, 2H\[\[2Hʹ\]), 3.52--3.47 (m,2H), 3.41--3.28 (m, 2H\[\[2Hʹ\]), 1.60--1.53 (m, 4H), 1.40--1.31 (m, 3H), 1.28--1.20 (m, 3H\[\[3Hʹ\]). ^13^C-NMR (100 MHz, CDCl~3~) δ 169.8, 143.3, 129.2, 123.5 and \[\[123.9, (1Cʹ)\], 114.1 and \[\[114.7, (1Cʹ)\], 87.1 and \[\[88.0, (1Cʹ)\], 77.8, 71.8, 71.2, 61.6, 48.8 and \[\[49.5, (1Cʹ)\], 31.7, 19.3, 14.2, 14.0. HRMS (EI^+^) exact mass calculated for C~17~H~24~ClNO~4~ \[M\]^+^ requires *m*/*z* 341.1394, found *m*/*z* 341.1397.

*Ethyl 3-(4-chlorophenyl)-5-(isopropoxymethyl)oxazolidine-2-carboxylate* (**3i**) (**diastereoisomers**): Light yellow liquid; R*~f~* = 0.52 (1:5 ethyl acetate:petroleum ether); 54% yield. The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 95/5, flow rate 1 mL/min, λ = 254 nm), t~R~ = 6.73 min (major), t~R~ = 7.82 min (minor), 90% *ee*; ^1^H-NMR (400 MHz, CDCl~3~) δ 7.20--7.17 (m, 2H\[\[2Hʹ\]), 6.59--6.54 (m, 2H\[\[2Hʹ\]), 5.40 (s, 1H) and \[\[5.43, (s, 1Hʹ)\], 4.86--4.82 (m, 1H\[\[1Hʹ\]), 4.22--4.15 (m, 2H\[\[2Hʹ\]), 3.75--3.64 (m, 2H\[\[2Hʹ\]), 3.63--3.57 (m, 2H\[\[2Hʹ\]), 3.31--3.27 (m, 1H\[\[1Hʹ\]), 1.31--1.24 (m, 3H\[\[3Hʹ\]), 1.22--1.16 (m, 6H\[\[6Hʹ\]), ^13^C-NMR (100 MHz, CDCl~3~) δ 169.8, 143.4, 129.2, 123.5, 114.1 and \[\[114.7, (1Cʹ)\], 87.9 and \[\[88.0, (1Cʹ)\], 78.0, 72.6, 68.7 and \[\[69.6, (1Cʹ)\], 61.6, 49.0 and \[\[49.7, (1Cʹ)\], 22.1, 14.2. HRMS (ESI^+^) exact mass calculated for \[M + Na\]^+^ requires *m*/*z* 350.1130, found *m*/*z* 350.1131.

*Ethyl 3-(4-methoxyphenyl)-5-phenyloxazolidine-2-carboxy-late* (**3j**) (**diastereoisomers**): Light yellow solid; M.P.: 53--56 °C; R*~f~* = 0.50 (1:5 ethyl acetate:petroleum ether); 42% yield. The enantiomeric excess (*ee*) was determined by HPLC on a Chiralcel OD-H column (*n*-hexane/isopropanol = 99/1, flow rate 0.30 mL/min, λ = 254 nm), t~R~ = 28.61 min (major), t~R~ = 30.667 min (minor), 84.6% *ee*; ^1^H-NMR (400 MHz, CDCl~3~) δ 7.50--7.48 (d, 2H), 7.33--7.32 (m, 3H), 6.79--6.73 (m, 2H), 6.71--6.66 (m, 2H), 5.50 (s, 1H) 4.36--4.27 (m, 2H), 4.24--4.16 (m, 2H), 4.05--4.02 (m, 1H), 3.72 (s, 3H) 1.40--1.37 (m, 3H), ^13^C-NMR (100 MHz, CDCl~3~) δ 170.70, 153.06,139.84, 139.19, 128.91, 127.83, 126.52, 114.88, 114.65, 90.85, 75.37, 63.75, 61.53, 55.59, 14.21. HRMS (EI^+^) exact mass calculated for C~19~H~21~NO~4~ \[M\]^+^ requires *m*/*z* 327.1471, found *m*/*z* 327.1471.

4. Conclusions {#sec4-molecules-20-17208}
==============

In conclusion, we disclosed an efficient asymmetric three-component reaction of anilines, ethyl glyoxalates, and epoxides, yielding 1,3-oxazolidine derivatives with high diastereo and enantioselectivities (up to 20:1 d.r., 90% *ee*) by cascade process. This reaction provides a convenient method to synthesize multi-substituted 1,3-oxazolidine compounds of high optical purity. The plausible mechanism was suggested and a kinetic resolution process was confirmed. All of the products in this paper were well-characterized and the absolute configuration of the chiral center from epoxides was determined. We believe this study will enrich the methodologies for the synthesis of five-membered oxacycles and natural products. Further studies are underway and other synthetic applications will be reported in a due time.
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